Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Von Hoff DD, et al. Among authors: renschler mf. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16. N Engl J Med. 2013. PMID: 24131140 Free PMC article. Clinical Trial.
Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. "A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis." Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011.
Von Hoff DD, Renschler MF. Von Hoff DD, et al. Among authors: renschler mf. Ther Adv Med Oncol. 2017 Jun;9(6):441-443. doi: 10.1177/1758834017699772. Epub 2017 Apr 16. Ther Adv Med Oncol. 2017. PMID: 28607582 Free PMC article. No abstract available.
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Socinski MA, et al. Among authors: renschler mf. J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547591 Clinical Trial.
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Yardley DA, et al. Among authors: renschler mf. Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7. Trials. 2015. PMID: 26673577 Free PMC article. Clinical Trial.
Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N, Chawla SP, Chiorean EG, Read WL, Gorbaty M, Mita AC, Yung L, Bryan P, McNally R, Renschler MF, Sharma S. Chen N, et al. Among authors: renschler mf. Cancer Chemother Pharmacol. 2013 Apr;71(4):1083-94. doi: 10.1007/s00280-013-2093-1. Epub 2013 Feb 12. Cancer Chemother Pharmacol. 2013. PMID: 23400695 Clinical Trial.
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H, Renschler MF. Socinski MA, et al. Among authors: renschler mf. Ann Oncol. 2013 Sep;24(9):2390-6. doi: 10.1093/annonc/mdt235. Epub 2013 Jul 10. Ann Oncol. 2013. PMID: 23842283 Free article. Clinical Trial.
40 results